NinaBhardwajMD

Rheumatology • New York, NY

Professor, Medicine, New York University School of Medicine

Join to view full profile

Dr. Bhardwaj is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhardwaj's full profile

Already have an account?

Office
522 1st Ave
New York, NY 10016

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Rheumatology, 1986 - 1987
Brigham and Women's HospitalResidency, Internal Medicine, 1981 - 1983
New York University School of MedicineClass of 1981

Certifications & Licensure

NY State Medical License 1983 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1999

Clinical Trials

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients Start of enrollment: 2000 Nov 01
Completed
Phase 1
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine Start of enrollment: 2005 Jul 01
Completed
Phase 1
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Start of enrollment: 2005 Aug 24
Completed
Phase 1
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Start of enrollment: 2006 Mar 21
Completed
Phase 1
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Start of enrollment: 2009 Feb 01
Completed
Phase 1
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma Start of enrollment: 2012 Oct 01
Terminated
Phase 2
PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2014 Jan 01
Terminated
Not Applicable
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma Start of enrollment: 2014 Apr 09
Completed
Phase 2
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® Start of enrollment: 2015 Mar 01
Completed
Phase 2
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Start of enrollment: 2016 Dec 28
Completed
Phase 1, Phase 2
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies Start of enrollment: 2016 Apr 01
Completed
Phase 1
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 Start of enrollment: 2018 Sep 25
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

28 citations
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlle...
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul
Eclinicalmedicine. 2022-03-01
27 citations
Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation.
Christian Rolfo, Noy Meshulami, Alessandro Russo, Florian Krammer, Adolfo García-Sastre
Journal of Thoracic Oncology. 2021-11-10
17 citations
New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
Evan Greene, Greg Finak, Leonard A D'Amico, Nina Bhardwaj, Candice D. Church
Patterns. 2021-10-27

Journal Articles

A Natural Killer–Dendritic Cell Axis Defines Checkpoint Therapy–Responsive Tumor Microenvironments
Patrick K Ha, William R Ryan, Nina Bhardwaj, Vincent Chan, Michael D Alvarado, Adil I Daud, Joy Hsu, Nature